433 related articles for article (PubMed ID: 26880855)
41. New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?
Li M; Zhang Y; Jiang L; Li Y; Li G; Zhou J; Yang C; Li X; Qu W; Chen Y; Chen Q; Wang S; Xing J; Huang H
Neoplasma; 2022 May; 69(3):729-740. PubMed ID: 35471981
[TBL] [Abstract][Full Text] [Related]
42. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
[TBL] [Abstract][Full Text] [Related]
43. The diagnostic value of tumor markers in bronchoalveolar lavage fluid for the peripheral pulmonary carcinoma.
Zhang S; Zhao YF; Zhang MZ; Wu XL
Clin Respir J; 2017 Jul; 11(4):481-488. PubMed ID: 26260621
[TBL] [Abstract][Full Text] [Related]
44. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer.
Zhang ZH; Han YW; Liang H; Wang LM
Cancer Med; 2015 Nov; 4(11):1633-8. PubMed ID: 26333429
[TBL] [Abstract][Full Text] [Related]
45. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
46. Combining serum miRNAs, CEA, and CYFRA21-1 with imaging and clinical features to distinguish benign and malignant pulmonary nodules: a pilot study : Xianfeng Li et al.: Combining biomarker, imaging, and clinical features to distinguish pulmonary nodules.
Li X; Zhang Q; Jin X; Cao L
World J Surg Oncol; 2017 May; 15(1):107. PubMed ID: 28545454
[TBL] [Abstract][Full Text] [Related]
47. Identification of Circulating miR-762 as a Novel Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer.
Chen L; Li Y; Lu J
Technol Cancer Res Treat; 2020; 19():1533033820964222. PubMed ID: 33317398
[TBL] [Abstract][Full Text] [Related]
48. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC).
Cedrés S; Nuñez I; Longo M; Martinez P; Checa E; Torrejón D; Felip E
Clin Lung Cancer; 2011 May; 12(3):172-9. PubMed ID: 21663860
[TBL] [Abstract][Full Text] [Related]
49. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
50. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
51. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
52. [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer].
Huang F; Wang XL; Yang L; Yin BX; Geng Y; Li TT
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr; 24(4):370-2. PubMed ID: 18394347
[TBL] [Abstract][Full Text] [Related]
53. [Clinical value of CEA and CYFRA21-1 as an assessment indicator of therapeutic efficacy in advanced non-small cell lung cancer patients].
Li L; Song LH; Ding SC; Zhang XJ; Qiang L; Han CY; Yuan XT; Xu DD
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):850-4. PubMed ID: 21223692
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic Value of Serum miR-182, miR-183, miR-210, and miR-126 Levels in Patients with Early-Stage Non-Small Cell Lung Cancer.
Zhu W; Zhou K; Zha Y; Chen D; He J; Ma H; Liu X; Le H; Zhang Y
PLoS One; 2016; 11(4):e0153046. PubMed ID: 27093275
[TBL] [Abstract][Full Text] [Related]
55. Serum carbohydrate sulfotransferase 7 in lung cancer and non-malignant pulmonary inflammations.
Debeljak Ž; Dundović S; Badovinac S; Mandić S; Samaržija M; Dmitrović B; Miloš M; Maričić L; Šerić V; Buljanović V
Clin Chem Lab Med; 2018 Jul; 56(8):1328-1335. PubMed ID: 29648993
[TBL] [Abstract][Full Text] [Related]
56. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer.
Reinmuth N; Brandt B; Semik M; Kunze WP; Achatzy R; Scheld HH; Broermann P; Berdel WE; Macha HN; Thomas M
Lung Cancer; 2002 Jun; 36(3):265-70. PubMed ID: 12009236
[TBL] [Abstract][Full Text] [Related]
57. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
58. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
[TBL] [Abstract][Full Text] [Related]
59. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
60. Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer.
Zhao H; Shi X; Liu J; Chen Z; Wang G
J Cancer Res Ther; 2014 Nov; 10 Suppl():C215-7. PubMed ID: 25450285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
